Literature DB >> 33099713

Surgical management and long-term outcomes of primary intracranial leiomyosarcoma: a case series and review of literature.

Gui-Jun Zhang1,2, Jian-Cong Weng1, Xu-Lei Huo1, Jun-Peng Ma1, Bo Wang1, Liang Wang1, Huan Li3, Da Li1, Jun-Ting Zhang1, Zhen Wu4.   

Abstract

Primary intracranial leiomyosarcomas (PILMSs) are extremely rare neoplasms, and their management remains unclear. The authors aimed to enunciate the radiological features and design a treatment protocol based on previously published cases combined with our series. Clinical data from all 12 cases of PILMS treated at their institute between 2008 and 2018 were reviewed. Meanwhile, they searched the Ovid MEDLINE, Embase, PubMed, Web of Science and Cochrane databases using the keywords "leiomyosarcoma" and "intracranial," "central nervous system," "cerebral," or "brain" Previously published data were processed and used according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The authors' cohort included 4 males (33.3%) and 8 females (66.7%) ranging in age from 13 to 67 years with a mean of 44.1 ± 5.0 years. Gross total resection (GTR), subtotal resection, and partial resection were achieved in 8 (66.7%), 3 (25%), and 1 (8.3%) patient, respectively, and only four patients (33.3%) received adjuvant therapy after surgery. After a mean follow-up of 30.5 ± 7.6 months, 6 patients (50%) experienced recurrences, and all of them died at the final. Twenty-seven patients (15 were male and 12 were female), in the literature cases, were identified between January 1980 and November 2019, presenting with PILMS. GTR and non-GTR were achieved in 21 (77.8%) and 6 (22.2%) patients, respectively. Postoperative radiotherapy was administrated in 17 patients (63.0%), and postoperative chemotherapy was administrated in 9 patients (33.3%), After a mean follow-up of 22.2 ± 4.1 months, recurrence and death occurred in 8 (36.4%) and 4 (14.8%) cases, respectively. In the pooled cases, the univariate analysis model revealed that only GTR was a significantly favorable factor for increased progression-free survival (hazard ratio 0.270, 95% confidence interval = 0.093-0.787, p = 0.016) and overall survival (hazard ratio 0.255, 95% confidence interval = 0.073-0.890, p = 0.032). GTR was recommended as an optimal treatment; meanwhile, postoperative radiation was also a choice to help increase the survival of patients of PILMS.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Primary intracranial leiomyosarcoma; Prognosis; Treatment strategy

Year:  2020        PMID: 33099713     DOI: 10.1007/s10143-020-01422-z

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  23 in total

1.  Primary dural leiomyosarcoma in a patient infected with human immunodeficiency virus: case report.

Authors:  G K Bejjani; B Stopak; A Schwartz; R Santi
Journal:  Neurosurgery       Date:  1999-01       Impact factor: 4.654

2.  Primary intracranial leiomyosarcoma in an immunocompetent patient.

Authors:  M Almubaslat; J C Stone; L Liu; Z Xiong
Journal:  Clin Neuropathol       Date:  2011 May-Jun       Impact factor: 1.368

3.  Primary intracranial leiomyosarcoma of the torcular Herophili associated with Fanconi anemia and allogenic stem cell transplantation.

Authors:  Michèle Aumüller; Karl-Walter Sykora; Christian Hartmann; Elvis J Hermann; Joachim K Krauss
Journal:  Childs Nerv Syst       Date:  2014-04-22       Impact factor: 1.475

4.  Primary leiomyosarcoma of the dura mater. Case report.

Authors:  A Asai; H Yamada; S Murata; A Matsuno; K Tsutsumi; T Takemura; M Matsutani; K Takakura
Journal:  J Neurosurg       Date:  1988-02       Impact factor: 5.115

Review 5.  Primary intracranial leiomyosarcoma in an immunocompetent patient: Case report and review of the literature.

Authors:  Shannon J Gallagher; Stephen A Rosenberg; David Francis; Shahriar Salamat; Steven P Howard; Randall J Kimple
Journal:  Clin Neurol Neurosurg       Date:  2018-01-06       Impact factor: 1.876

6.  Primary intracranial leiomyosarcoma.

Authors:  Babak Alijani; Shahrokh Yousefzade; Ali Aramnia; Alireza Mesbah
Journal:  Arch Iran Med       Date:  2013-10       Impact factor: 1.354

7.  Intracranial leiomyosarcoma in a patient with AIDS.

Authors:  H G Brown; P C Burger; A Olivi; A K Sills; P A Barditch-Crovo; R R Lee
Journal:  Neuroradiology       Date:  1999-01       Impact factor: 2.804

8.  Primary cerebral leiomyosarcoma in a child.

Authors:  Boris P Eckhardt; Sebastian Brandner; Christoph L Zollikofer; Klaus U Wentz
Journal:  Pediatr Radiol       Date:  2004-04-01

9.  Primary intracranial leiomyosarcoma. Case report with ultrastructural study.

Authors:  W R Anderson; J D Cameron; S H Tsai
Journal:  J Neurosurg       Date:  1980-09       Impact factor: 5.115

10.  Primary intracranial leiomyosarcoma presenting with massive peritumoral edema and mass effect: Case report and literature review.

Authors:  Sachidanand Gautam; Rajesh K Meena
Journal:  Surg Neurol Int       Date:  2017-11-20
View more
  2 in total

1.  Management of non-vestibular schwannomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section Part II: Trigeminal and facial nerve schwannomas (CN V, VII).

Authors:  Jarnail Bal; Michael Bruneau; Moncef Berhouma; Jan F Cornelius; Luigi M Cavallo; Roy T Daniel; Sebastien Froelich; Emmanuel Jouanneau; Torstein R Meling; Mahmoud Messerer; Pierre-Hugues Roche; Henry W S Schroeder; Marcos Tatagiba; Idoya Zazpe; Dimitrios Paraskevopoulos
Journal:  Acta Neurochir (Wien)       Date:  2022-01-25       Impact factor: 2.216

2.  Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review.

Authors:  Liyan Zhao; Yining Jiang; Yubo Wang; Yang Bai; Ying Sun; Yunqian Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.